

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT: JULY 18, 2000
(Date of earliest event reported)

INCYTE GENOMICS, INC.
(FORMERLY INCYTE PHARMACEUTICALS, INC.)
(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation)	0-27488 (Commission File Number)	94-3136539 (IRS Employer Identification No.)
3160 PORTER DRIVE, PALO ALTO, CALIFORNIA (Address of principal executive offices)		94304 (Zip Code)

Registrant's telephone number, including area code: (650) 855-0555

Item 5. Other Events.

Attached hereto as Exhibit 99.1 and incorporated by reference herein is the press release dated July 18, 2000 announcing that Incyte's board of directors have approved a two-for-one stock split in the form of a stock dividend. Incyte stockholders of record at the close of business on August 7, 2000 will receive one additional share for each share of common stock held at the time. The additional shares will be distributed to eligible stockholders on August 31, 2000.

Item 7. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press release dated July 18, 2000.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 18, 2000

INCYTE GENOMICS, INC.

By /s/ John M. Vuko

Name: John M. Vuko
Title: Executive Vice President and
Chief Financial Officer

FOR IMMEDIATE RELEASE

INCYTE
John Vuko
Chief Financial Officer
(650) 845-4106

INCYTE ANNOUNCES 2-FOR-1 STOCK SPLIT

PALO ALTO, CALIFORNIA, JULY 18, 2000 -- Incyte Genomics, Inc. (Nasdaq: INCY), today announced that its board of directors has approved a two-for-one stock split in the form of a stock dividend. Incyte stockholders of record at the close of business on August 7, 2000 will receive one additional share for each share of common stock held at that time. The additional shares will be distributed to eligible stockholders on August 31, 2000. The stock split will increase the number of shares of common stock outstanding from approximately 32 million to approximately 64 million.

Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at www.incyte.com.

Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2000. Incyte disclaims any intent or obligation to update these forward-looking statements.

###